Piribedil maleate | 937719-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Piribedil maleate
• 英文别名: 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine;(Z)-but-2-enedioic acid
• CAS: 937719-94-3
• 化学式: C20H22N4O6
• 分子量: 414.4
• InChiKey: DKGOFBARSQSLOW-BTJKTKAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.24
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Compositions and methods for the treatment of Zellweger spectrum disorder
  申请人：Hacia Joseph

  公开号：US11065247B2

  公开（公告）日：2021-07-20

  Provided herein are methods of treating Zellweger spectrum disorder (ZSD) in a subject in need thereof or improving peroxisome assembly in a cell in need thereof comprising administering to the subject a therapeutically effective amount of Compounds of Formula I or II.

  本文提供了在有需要的受试者中治疗泽尔维格谱系障碍（ZSD）或在有需要的细胞中改善过氧物酶体组装的方法，包括向受试者施用治疗有效量的式 I 或式 II 化合物。
• METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE
  申请人：Tyers Mike

  公开号：US20090076019A1

  公开（公告）日：2009-03-19

  A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER
  申请人：Hacia Joseph

  公开号：US20180000814A1

  公开（公告）日：2018-01-04

  Provided herein are methods of treating Zellweger spectrum disorder (ZSD) in a subject in need thereof or improving peroxisome assembly in a cell in need thereof comprising administering to the subject a therapeutically effective amount of Compounds of Formula I or II.
• US8058243B2
  申请人：——

  公开号：US8058243B2

  公开（公告）日：2011-11-15
• [EN] OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS<br/>[FR] FORMULATION OPHTALMIQUE CONTENANT UN PROMÉDICAMENT DOPAMINERGIQUE QUI PEUT ÊTRE COMBINÉ À UN OU PLUSIEURS AGENTS
  申请人：[en]THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：WO2022099195A1

  公开（公告）日：2022-05-12

  The invention described herein relates to a prodrug that is converted into a dopamine agonist. The dopamine prodrug may be combined with one or more dopamine antagonists, dopamine receptor inhibitors, or vesicular monoamine transport inhibitors. A prodrug is a biologically inactive compound that can be metabolized by the body into its active form. For example, a prodrug placed on the ocular surface can undergo hydrolysis during penetration of the ocular surface, resulting in a biologically active drug. A prodrug allows for use of a lower concentration of the drug and protects against undesirable side effects. A prodrug can also help augment drug uptake into the target tissue.